التفاصيل البيبلوغرافية
| العنوان: |
Renal effects of immune checkpoint inhibitors. |
| المؤلفون: |
Izzedine, Hassan, Mateus, Christine, Boutros, Céline, Robert, Caroline, Rouvier, Philippe, Amoura, Zahir, Mathian, Alexis |
| المصدر: |
Nephrology Dialysis Transplantation; Jun2017, Vol. 32 Issue 6, p936-942, 7p, 3 Charts |
| مصطلحات موضوعية: |
ONCOLOGY, T cells, APOPTOSIS, NEPHRITIS, GLOMERULONEPHRITIS |
| مستخلص: |
Recent advances in immune checkpoint inhibitor (ICPI) development have led to major improvements in oncology patient outcomes. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are two essential immune checkpoint receptors. Ipilimumab and tremelimumab (anti-CTLA-4-blocking antibodies) and and nivolumab (antibodies targeting PD-1 receptors) have already been approved by US Food and Drug Administration in several malignancies. Two different forms of ICPI-induced renal damage have been identified, including acute (granulomatous) tubulointerstitial nephritis and immune complex glomerulonephritis. The observed acute renal damage can be reversed upon ICPI drug discontinuation and renal function can recover back to normal following the introduction of systemic corticosteroid treatment. Any delay in treating this complication could result in definitive and irreversible renal injury. [ABSTRACT FROM AUTHOR] |
|
Copyright of Nephrology Dialysis Transplantation is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder